CD200 (Gene)

Synonyms:CD200 molecule, CD200, ENTREZ:4345, HGNC:7203, MIM:155970, MOX1, MOX2, MRC, NM_001004196, NM_001004197, NM_001318826, NM_001318828, NM_001318830, NM_001365851, NM_001365852, NM_001365853, NM_001365854, NM_001365855, NM_005944, NP_001004196, NP_001305755, NP_001305757, NP_001305759, NP_001352780, NP_001352781, NP_001352782, NP_001352783, NP_001352784, NP_005935, NR_158642, OX-2
Omim:OMIM:155970
Id:ENSG00000091972
Hgnc:HGNC:7203
Entrez:4345
Description:CD200 molecule
This gene encodes a type I membrane glycoprotein containing two extracellular immunoglobulin domains, a transmembrane and a cytoplasmic domain. This gene is expressed by various cell types, including B cells, a subset of T cells, thymocytes, endothelial cells, and neurons. The encoded protein plays an important role in immunosuppression and regulation of anti-tumor activity. Alternative splicing results in multiple transcript variants encoding different isoforms. [provided by RefSeq, Jan 2016]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View CD200's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with CD200.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using CD200.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for CD200.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with CD200.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.